Promising First Results With DNA Editing to Lower LDL

The first-in-human HEART-1 trial of in vivo DNA editing called VERVE-101, shows reductions in LDL and PCSK9 protein in patients with familial hypercholesterolemia.

Related Keywords

Philadelphia ,Pennsylvania ,United States ,American ,Andrew Bellinger ,Karol Watson ,Amgen ,Novartis ,American Heart Association ,Verve Therapeutics ,American Heart ,Lipids ,Ipid Management ,Cv ,Ardiovascular ,Pcsk9 ,Roprotein Convertase Subtilisin Kexin Type 9 ,Genomics ,Genomic Medicine ,Edicine Genomic ,Liver ,Aminotransferase ,Dust ,Liver Enzymes ,Liver Studies ,Olt ,Familial Hypercholesterolemia ,Hypercholesterolemia ,Gene Editing ,Genetic Editing ,Low Ldl Cholesterol ,Ypobetalipoproteinemia ,Ow Low Density Lipoprotein Cholesterol ,Biologic Therapy ,Gene Ther ,